Celiac Disease Drugs Market Size
The Global Celiac Disease Drugs Market reached US$ 763.2 million in 2025 and is expected to reach US$ 1,862.6 million by 2033, growing with a CAGR of 11.4% during the forecast period 2026-2033.
Celiac disease is a genetic, auto-immune disorder that affects the small intestine upon consumption of gluten. Celiac diseases may contribute to various diseases and disorders such as low bone density, neurological disorders, infertility, and certain cancers.
Celiac Disease Drugs Market Scope
| Metrics | Details |
| Market CAGR | 11.4% |
| Segments Covered | By Enzyme Type, By Drugs, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Celiac Disease Drugs Market Dynamics
The global celiac disease drugs market growth is driven by the increasing prevalence of celiac diseases population. In addition, strong research and development activities to bring newer treatment are some of the impacting factors that drives the market growth. Moreover, special designation such as orphan drug designation and fast track designation are considered a positive indicator for rise in market growth.
Initiatives by the governments will drive the growth of the market
Governments of different countries such as the U.K., Canada, New Zealand, Australia, and Argentina and the European Union are expected to accelerative initiatives for the treatment of celiac disease. These governments could provide a strong boost to the global celiac disease drugs market while riding on therapeutics offered at subsidized prices, increasing awareness among the people, and funds offered to research and development activities. Canada and Argentina are predicted to impose labeling restrictions on gluten-rich packaged foods and also those free of gluten to keep the spread of celiac disease at bay. Initiatives such as the National Program for the Detection and Control of Celiac Disease by Argentina are anticipated to be a good step taken to counter the disease.
The rise in demand from millennials, increase in the incidence of celiac disease
It is hard to maintain 100% gluten-free diet and accidental gluten cross-contamination cannot be avoided, so researchers such as ImmunogenX are focused on finding alternative therapies and possibly even a cure for the disorder. Major pipeline molecules include bl-7010 (binds gluten so it is not absorbed), larazotide acetate (interrupt the immediate or delayed effects of gluten on the cells lining the intestine), and vedolizumab (interrupt the immune reactions). Rise in demand from millennial, rise in research and development expenditure, and growth in awareness about celiac disease are factors fuelling the growth of the celiac disease market.
The high cost of a gluten-free diet is likely to hinder the market growth
However, high cost of gluten-free diet, lack of confidence of pipeline molecules, and the frequency of the disease being undiagnosed or misdiagnosed as an allergy are restraining the celiac disease market growth. Many low-income earning people can not afford these diets. Also, many underdeveloped areas do have not the proper infrastructure to process the gluten-free diet.
Celiac Disease Drugs Market Segmentation Analysis
The diarrhea segment is expected to grow at the fastest CAGR during the forecast period 2024-2031
Diarrhea is a bowel movement (stool) that is loose and watery. It is one of the common, non-serious conditions and can be treated with over-the-counter medicines. Numerous people experience diarrhea once or twice a year. It is estimated that globally, approximately 2 billion cases of diarrheal diseases occur each year, and about 1.9 million children (below five years of age), mostly found in developing countries, die from diarrhea. All these factors are contributing and showing the impact of celiac disease.
In one small study, 79% of celiac patients reported experiencing diarrhea prior to treatment. Following treatment, just 17% of patients continued to have chronic diarrhea. Another study of 215 people noted that diarrhea was the most frequent symptom of untreated celiac disease. For many patients, diarrhea was reduced within a few days of treatment, but the average time to fully resolve symptoms was four weeks.
Decreased energy levels and fatigue are prevalent in those with celiac disease. One study of 51 celiac patients found that those who were untreated had significantly more severe fatigue and fatigue-related problems than those on a gluten-free diet. Another study found that those with celiac disease were more likely to have sleep disorders, which could contribute to fatigue. Additionally, untreated celiac disease can cause damage to the small intestine, resulting in vitamin and mineral deficiencies that may also lead to fatigue. These factors are driving the growth of the market in the forecast period.
Celiac Disease Drugs Companies and Competitive Landscape
The celiac disease drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Innovate Biopharmaceuticals, Teva Pharmaceutical Industries Ltd, ImmunogenX, LLC, Amgen, ChemoCentryx, Inc, Anokion SA, COUR Pharmaceutical, F. Hoffmann-La Roche Ltd, ImmusanT, Inc, BioLineRx Ltd, and Takeda Pharmaceutical Company Limited, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the celiac disease drugs market globally.
Key Companies to Watch
Innovate Pharmaceuticals Limited
Overview: Innovation Pharmaceuticals develops small molecule therapies to treat cancer, antibiotics, and inflammatory disease. The company focuses on the development of compounds, including INN-202 (larazotide acetate) is a drug for celiac which is in pipeline that uses a potent digestive enzyme that appears to be able to break down gluten before your immune system can react to it. The results of phase II clinical trial were promising and demonstrated that the drug was both safe and tolerable.
Product Portfolio: The Company’s portfolio comprised of anti-cancer agents, small molecule therapies to treat cancer, antibiotics, and inflammatory disease, asthma drugs and others.
Recent Developments
- April 2026 – Pipeline expands with 30+ drug candidates across multiple mechanisms
More than 30 pipeline therapies are under development, including monoclonal antibodies, enzyme therapies, and immunomodulators, indicating strong R&D momentum across global pharmaceutical companies. - March 2026 – Teva advances TEV-53408 (anti-IL-15 antibody) in Phase 2 clinical trials
Teva Pharmaceutical Industries is progressing TEV-53408, a monoclonal antibody targeting IL-15 to reduce immune-mediated intestinal inflammation, with Phase 2 trials ongoing through 2026. - March 2026 – Enzyme-based therapies (e.g., latiglutenase / TAK-062) reach late-stage development
Oral enzyme therapies designed to break down gluten before immune activation are advancing into Phase 3 trials, potentially serving as adjunct protection against accidental gluten exposure. - February 2026 – ZED1227 (transglutaminase 2 inhibitor) shows promise in immune-targeted therapy
ZED1227 targets the key enzyme triggering autoimmune response, representing a shift toward disease-modifying therapies rather than symptom management. - February 2026 – Immunotherapy approaches (KAN-101, VTP-1000) aim to induce immune tolerance
Emerging therapies are focusing on retraining the immune system to tolerate gluten, with candidates like VTP-1000 and KAN-101 in early- to mid-stage trials. - January 2026 – Monoclonal antibodies (e.g., Amlitelimab) target inflammatory pathways
Biologic drugs such as Amlitelimab are being studied for non-responsive celiac disease, aiming to suppress immune signaling pathways responsible for intestinal damage. - January 2026 – Forte Biosciences advances FB102 monoclonal antibody trials
A Phase 2 clinical study (FB102-301) is underway evaluating a monoclonal antibody designed to block immune signaling triggered by gluten, with patient recruitment ongoing in 2026.
